To determine the pharmacokinetic properties, tolerance and safety of 2 formulations of
saquinavir, given in combination with 2 nucleoside antiretroviral drugs (part 1) or in
combination with nelfinavir and nucleoside antiretroviral drugs (part 2), in HIV-infected
infants and children.
This Phase I/II study will be conducted in 2 parts each lasting at least 24 weeks.
Pharmacokinetics and safety data for part 1, a treatment regimen containing saquinavir and
nucleoside antiretrovirals, will be collected for 8 weeks before proceeding to part 2.
During the first 8 weeks, pharmacokinetic data will be analyzed to allow dose adjustments
for individual patients and to confirm the starting dose estimates for part 2. In addition,
safety data will be reviewed to ensure that saquinavir is well tolerated with nucleoside
antiretrovirals before it is combined with a second protease inhibitor. In part 2,
saquinavir will be combined with nelfinavir, a protease inhibitor recently approved for use
in children. The pharmacokinetics and safety profile of these drugs in combination will be
Patients must have:
- HIV infection according to standard definitions employed by the Pediatric AIDS
Clinical Trials Group.
- Laboratory evidence of immunosuppression (Centers for Disease Control and Prevention
[CDC] categories 2 and 3), or symptomatic HIV disease (CDC categories A, B, and C).
- At least 4 patients (2 in each parts 1 and 2) will be enrolled in each of three age
- 6 months to 2 years; greater than 2 years to 6 years; and greater than 6 years to 13
- For the purposes of analysis only, patients will be stratified by age.
1. Patients must be protease inhibitor therapy naive.
- Antiretroviral agents other than those prescribed by the investigator.
- Biologic response modifiers (other than erythropoietin, G-CSF, short course [<14
days] corticosteroids, or intravenous immune globulin).
- Other investigational drugs.
- Drugs known to significantly interact with saquinavir and/or nelfinavir. Patients
must be protease inhibitor therapy naive.